Barclays lowered the firm’s price target on Cellectis (CLLS) to $5 from $7 and keeps an Overweight rating on the shares following the Q3 report.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLLS: